文献速递肝病消化道肿瘤与早癌

卡博替尼联合治疗肝细胞癌的临床前研究

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
PubMed 文献 · Gut · 2020-11-03

该研究在体外和体内评估卡博替尼单药或联合mTOR抑制剂MLN0128或抗PD-L1抗体治疗肝细胞癌的疗效。卡博替尼通过抑制c-MET/ERK/p21/PKM2通路和VEGFR2诱导的血管生成发挥作用,与MLN0128联用可使c-Met/β-catenin小鼠肿瘤消退,但与抗PD-L1联用未显示额外获益。

要点

  • 卡博替尼单药对c-Met/β-catenin和Akt/c-Met小鼠肝癌有效,但对Akt/Ras和c-Myc肝癌效果有限。
  • 卡博替尼抑制c-MET和ERK活性,降低PKM2并增加p21,但不抑制Akt/mTOR cascade。
  • 卡博替尼联合mTOR抑制剂MLN0128可使c-Met/β-catenin小鼠肿瘤消退。

核心结论

  • c-MET/ERK/p21/PKM2 cascade和VEGFR2诱导的血管生成是卡博替尼治疗HCC的主要靶点。
  • 卡博替尼与mTOR抑制剂联合治疗可能对人类HCC有效。

研究设计与样本

  • 研究使用人HCC细胞系和HCC小鼠模型,评估卡博替尼单药或联合pan-mTOR抑制剂MLN0128或检查点抑制剂抗PD-L1抗体的疗效和靶向分子通路。

主要发现

  • 卡博替尼治疗使c-Met/β-catenin和Akt/c-Met小鼠HCC获得稳定疾病,而对Akt/Ras和c-Myc肝脏肿瘤疗效有限。
  • 卡博替尼有效抑制c-MET和ERK活性,导致HCC细胞及c-Met/β-catenin和Akt/c-Met HCC中PKM2降低和p21表达增加。
  • 卡博替尼未能抑制Akt/mTOR cascade。
  • 卡博替尼强烈抑制血管生成,与致癌驱动因素无关。
  • 卡博替尼对肿瘤浸润T细胞等肿瘤微环境参数影响有限,且未诱导PD-L1表达。

临床怎么用

  • 临床前证据提示卡博替尼联合mTOR抑制剂可能成为HCC治疗策略,但需进一步临床验证。
  • 卡博替尼联合免疫检查点抑制剂在HCC中的协同作用未获支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of cabozantinib, either alone or in combination, in vitro and in vivo. DESIGN: Human HCC cell lines and HCC mouse models were used to assess the therapeutic efficacy and targeted molecular pathways of cabozantinib, either alone or in combination with the pan-mTOR inhibitor MLN0128 or the checkpoint inhibitor anti-PD-L1 antibody. RESULTS: Cabozantinib treatment led to stable disease in c-Met/β-catenin and Akt/c-Met mouse HCC while possessing limited efficacy on Akt/Ras and c-Myc liver tumours. Importantly, cabozantinib effectively inhibited c-MET and ERK activity, leading to decreased PKM2 and increased p21 expression in HCC cells and in c-Met/β-catenin and Akt/c-Met HCC. However, cabozantinib was ineffective in inhibiting the Akt/mTOR cascade. Intriguingly, a strong inhibition of angiogenesis by cabozantinib occurred regardless of the oncogenic drivers. However, cabozantinib had limited impact on other tumour microenvironment parameters, including tumour infiltrating T cells, and did not induce programmed death-ligand 1 (PD-L1) expression. Combining cabozantinib with MLN0128 led to tumour regression in c-Met/β-catenin mice. In contrast, combined treatment with cabozantinib and the checkpoint inhibitor anti-PD-L1 antibody did not provide any additional therapeutic benefit in the four mouse HCC models tested. CONCLUSION: c-MET/ERK/p21/PKM2 cascade and VEGFR2-induced angiogenesis are the primary targets of cabozantinib in HCC treatment. Combination therapies with cabozantinib and mTOR inhibitors may be effective against human HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Shang R, Song X, Wang P, et al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut. 2020. PMID: 33144318. doi:10.1136/gutjnl-2020-320716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。